Summary
Amgen Inc. announced on September 10, 2012, the pricing of a significant debt offering consisting of two series of Senior Notes. The company will issue €675,000,000 in Senior Notes due 2019 with a 2.125% annual interest rate and £700,000,000 in Senior Notes due 2029 with a 4.000% annual interest rate. These notes are being offered and sold exclusively outside the United States under Regulation S of the Securities Act of 1933, meaning they are not registered for sale within the U.S. This offering represents Amgen's strategy to raise capital through international debt markets. The funds are intended for general corporate purposes. Investors should note the specific terms of each note series, including their respective interest rates and maturity dates, as well as the fact that these securities are not available to U.S. purchasers. The settlement for this offering is anticipated to occur on September 13, 2012.
Key Highlights
- 1Amgen priced an offering of €675 million Senior Notes due 2019.
- 2Amgen priced an offering of £700 million Senior Notes due 2019.
- 3The 2019 Notes carry an annual interest rate of 2.125%.
- 4The 2029 Notes carry an annual interest rate of 4.000%.
- 5The offering is being conducted outside the United States under Regulation S.
- 6The notes are not registered under the U.S. Securities Act and cannot be offered or sold in the U.S.
- 7Settlement for the offering is expected on September 13, 2012.